Abstract: This invention relates to the use of biomarker LRG1 as a biomarker for preeclampsia for use from the first trimester. Elevated levels of leucine-rich alpha 2 glycoprotein 1 (LRG1) can predict risk for the future development of preeclampsia or other hypertensive disorders of pregnancy. The predictive test will comprise the measurement of LRG1 protein, peptide fragment, DNA or RNA, from either blood, plasma, serum, urine, saliva or amniotic fluid. The invention provides a method and a test kit to assess the risk of pre-eclampsia in pregnant woman. The method or test can utilise antibodies to measure levels of LGR1 in a sample.

Abstract: An antenna for a body-centric wireless communication system comprises first and second radiating structures between which is located a ground plane and a feed structure. The feed structure comprises a feed line extending between the first radiating structure and the ground plane, and a slot formed in the ground plane. A pair of shorting posts connects the first radiating structure to the ground plane. The antenna is capable of simultaneously generating in-body radiation, on-body radiation and off-body radiation in the same frequency band.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof, and novel crystalline forms thereof.

Abstract: The invention provides a method for detecting desired Mycobacterium species in a sample, the method comprising the steps of: a) mixing mycobacteriophage-coupled paramagnetic particles with the sample to form a reaction mixture under conditions suitable to allow the mycobacteriophage to bind to any mycobacteriophage-sensitive Mycobacterium species present in the sample; b) applying a magnetic field to the sample to collect, and separate, mycobacteriophage-coupled paramagnetic particles with bound desired Mycobacterium species; c) incubating a suspension of the separated paramagnetic particles with bound Mycobacterium species under conditions to allow the mycobacteriophage to replicate inside viable Mycobacterium species cells and to lyse the viable Mycobacterium species cells; d) recovering, from the incubated suspension, nucleotide, optionally DNA, of lysed Mycobacterium species DNA; and e) analysing the nucleotide, optionally DNA, released from the lysed Mycobacterium species to identify a signature nucleoti

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present invention relates to a method of diagnosing ovarian cancer, including fallopian tube and/or primary peritoneal cancer. Specifically, the present invention relates to a method of diagnosing high grade serous carcinoma. The invention involves measuring the nucleic acid methylation levels of one or more biomarkers in the sample; and diagnosing ovarian cancer in the patient based on the nucleic acid methylation levels.

Abstract: The invention provides a wellbore fluid which comprises an aqueous continuous phase and, dissolved in said aqueous continuous phase, at least one salt containing an imidazolium cation having at least 6 carbon atoms, and a method of carrying out a wellbore operation, which comprises introducing into a wellbore in a clay-containing formation, a wellbore fluid according to the invention. The described salts are effective shale inhibitors.

Abstract: Methods of preparing nicotinamide riboside and derivatives thereof.

Abstract: This invention relates to a dispersion comprising porous particles dispersed in a liquid phase, wherein the porous particles comprise a zeolite and the liquid phase is a size-excluded liquid. The invention also relates to a method of adsorbing a gas into a liquid, comprising at least the step of bringing the gas into contact with the dispersion. In addition, the invention relates to an assemblage of the dispersion, the zeolite comprising a cavity and a gas contained within the cavity.

Abstract: The invention relates to dispersions of porous solids in liquids selected from deep eutectic solvents, liquid oligomers, bulky liquids, liquid polymers, silicone oils, halogenated oils, paraffin oils or triglyceride oils, as well as to their methods of preparation. In embodiments of the invention, the porous solids are metal organic framework materials (MOFs), zeolites, covalent organic frameworks (COFs), porous inorganic materials, Mobil Compositions of Matter (MCMs) or a porous carbon. The invention also relates to the use of porous materials to form dispersions, and to assemblages of such dispersions with a gas or gases. The dispersions can exhibit high gas capacities and selectivities.

Abstract: The invention provides methods of making microparticle and nanoparticle ocular implants from a compositions comprising: 99 to 60% (w/w) of a photopolymerizable composition selected from the group of fragments or monomers consisting of polyalkylene glycol diacrylate and polyalkylene glycol dimethacrylate, wherein the photopolymerizable composition has a molecular weight in the range of 100 to 20,000 Dalton; a biodegradable polymer selected from the group consisting of aliphatic polyester-based polyurethanes, polylactides, polycaprolactones, polyorthoesters and mixtures, copolymers, and block copolymers thereof; a photoinitiator; and a therapeutic agent.

Abstract: This invention relates to a process for the preparation of a dispersion comprising coloured or black particles, such coloured or black particles prepared by the process, the use of the dispersion and the coloured or black particles in electrophoretic fluids, and electrophoretic display devices comprising such fluids.

Abstract: Methods of preparing nicotinamide riboside and derivatives thereof, are described. In an aspect, the invention relates to a method of making a compound of formula (II), or a salt, or solvate thereof: wherein n is 0 or 1; Y is O or S; m is 1; R1 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted primary or secondary amino, and substituted or unsubstituted azido; and R2-R5 are each H.

Abstract: A method for extracting a rare earth metal from a mixture of one or more rare earth metals, said method comprising contacting an acidic solution of the rare earth metal with a composition which comprises an ionic liquid to form an aqueous phase and a non-aqueous phase into which the rare earth metal has been selectively extracted.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof, and novel crystalline forms thereof.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.